The purpose of this document is to support commissioners to act promptly to make the most of the opportunity presented by increased competition amongst biological medicines, including biosimilar medicines.

In particular, this framework seeks to set out the importance of taking a collaborative approach to the commissioning of biological medicines, including biosimilar medicines, from the outset, as well as setting out how this can be achieved.